Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 15 articles: HTML format

Single Articles

September 2021
1. FELIP E, Altorki N, Zhou C, Csoszi T, et al
   Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
   Lancet. 2021 Sep 17. pii: S0140-6736(21)02098.
   PubMed     Abstract available
   
   
   
2. GAINOR JF
   Adjuvant PD-L1 blockade in non-small-cell lung cancer.
   Lancet. 2021 Sep 17. pii: S0140-6736(21)02100.
   PubMed    
   
   
   July 2021
3. BAAS P, Scherpereel A, Nowak AK, Oukessou A, et al
   Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
   Lancet. 2021;398:302.
   PubMed    
   
   
   
4. DI MAIO M, Tagliamento M
   Heterogeneity of treatment effects in malignant pleural mesothelioma.
   Lancet. 2021;398:301-302.
   PubMed    
   
   
   
5. THAI AA, Solomon BJ, Sequist LV, Gainor JF, et al
   Lung cancer.
   Lancet. 2021 Jul 14. pii: S0140-6736(21)00312.
   PubMed     Abstract available
   
   
   March 2021
6. KHO SS, Ho YF, Chan SK, Tie ST, et al
   Mediastinal melioidosis masquerading as malignancy of the lung.
   Lancet. 2021;397:e8.
   PubMed    
   
   
   February 2021
7. SEZER A, Kilickap S, Gumus M, Bondarenko I, et al
   Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
   Lancet. 2021;397:592-604.
   PubMed     Abstract available
   
   
   
8. ROSELL R, Gonzalez-Cao M
   Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.
   Lancet. 2021;397:557-559.
   PubMed    
   
   
   January 2021
9. CERESOLI GL, Pasello G
   Immune checkpoint inhibitors in mesothelioma: a turning point.
   Lancet. 2021;397:348-349.
   PubMed    
   
   
   
10. BAAS P, Scherpereel A, Nowak AK, Fujimoto N, et al
    First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2021;397:375-386.
    PubMed     Abstract available
    
    
    
11. TREASURE T, Macbeth F, Farewell V, Williams NR, et al
    The fallacy of large survival gains from lung metastasectomy in colorectal cancer.
    Lancet. 2021;397:97-98.
    PubMed    
    
    
    August 2020
12. SZTURZ P, Vermorken JB
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:379.
    PubMed    
    
    
    
13. MCCAW ZR, Ludmir EB, Kim DH, Wei LJ, et al
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:378-379.
    PubMed    
    
    
    
14. REVANNASIDDAIAH S, Devadas SK, Maka VV, Kilara N, et al
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:378.
    PubMed    
    
    
    May 2020
15. HARRIS DA, Willis J, Tomann M
    A new era of coal workers' pneumoconiosis: decades in mines may not be required.
    Lancet. 2020;395:e82.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: